Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2019-09-23 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma annonce la présentation de données cliniques sur IPH5401 et monalizumab au congrès de l’ESMO 2019
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing the upcoming presentation of clinical trial data at the ESMO 2019 congress. It provides highlights of the research findings to be presented but does not constitute a full financial report, audit, or regulatory filing. As it is a corporate announcement regarding company activities and research updates, and given the 'Report Publication Announcement' (RPA) category is intended for announcements regarding the release of reports, this document fits best as a general regulatory announcement (RNS) as it is a standard corporate press release.
2019-09-23 French
Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing upcoming clinical data presentations at the ESMO 2019 Congress. It provides highlights of the research but does not contain the full clinical study reports or financial statements. It includes a link to an attachment titled 'PR in English', which confirms it is a corporate announcement. As it does not fit into specific categories like 10-K, IR, or CT, and serves as a general regulatory/corporate announcement, it is classified as a Regulatory Filing (RNS).
2019-09-23 English
Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing upcoming clinical data presentations at the ESMO 2019 Congress. It provides highlights of the research to be presented but does not contain the full financial reports or the actual clinical data sets themselves. It concludes with a standard 'Attachment' link to the press release, which is characteristic of a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of the announcement regarding corporate activities and the presence of an attachment link, it fits the definition of an RPA.
2019-09-23 English
Innate Pharma annonce la présentation de données cliniques sur IPH5401 et monalizumab au congrès de l’ESMO 2019
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing the upcoming presentation of clinical trial data at the ESMO 2019 congress. It provides highlights of the data to be presented but does not contain the full clinical study reports or financial statements. As it is a standard corporate announcement regarding company activities and upcoming events, and does not fit into more specific categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2019-09-23 French
Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing upcoming clinical data presentations at the ESMO 2019 Congress. It provides highlights of the research to be presented but does not contain the full financial report or the actual scientific data itself. It functions as a corporate announcement regarding company activities and research progress. According to the 'Menu vs Meal' rule, since this is a short announcement regarding information that will be presented elsewhere, and it includes an 'Attachment' link for the full press release, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement.
2019-09-23 English
Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing upcoming clinical data presentations at the ESMO 2019 Congress. It provides highlights of the research but does not contain the full financial reports or the actual scientific data sets. It concludes with a link to an attachment titled 'PR in English', which confirms it is a corporate announcement/regulatory filing regarding the publication of information. Given the nature of the content (announcing scientific presentations rather than financial results or governance changes), it falls under the RNS (Regulatory Filings) category as a general corporate announcement.
2019-09-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.